Cellectis to Host R&D/ Analyst Day on September 11th at Le Parker Meridien Hotel in New York City

Published on September 02, 2014

Back to all press releases

Genome Engineering & CART Cells: At the forefront of immuno-oncology

September 2, 2014 — New York (NY) — Cellectis (Alternext: ALCLS.PA), a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) will host a R&D/ Analyst Day on Thursday, September 11 at 7:30AM in New York City. 

 Cellectis’ scientists will provide an overview of the Company's therapeutic innovations. The event will also feature presentations by key opinion leaders: Pr. Laurence Cooper, MD Anderson Cancer Center ; Dr. Jaume Pons Senior Vice President and CSO of Rinat, the biotech unit of Pfizer and Eric Falcand, Director, Alliance Management & US Licenses at Servier Laboratories.



8:00 Welcome Remarks Dr. André Choulika, Ph.D. – Chairman & CEO of Cellectis

8:05 Keynote address – Pr. Laurence Cooper, MD, Ph.D. – University of Texas, MD Anderson Cancer Center, Houston, Texas (25mn)

8:30 The Discovery at Cellectis Dr. Philippe Duchateau, Ph.D. – Chief Scientific Officer (10 mn)

8:40 Genome Engineering Technologies Dr. Julien Valton, Ph.D. – Project Leader (20 mn)

9:00 Editing the T Cell Genome Dr. Laurent Poirot, Ph.D. – Head of Early Discovery (20 mn)

9:20 Dr. Jaume Pons, Ph.D. – Senior Vice President and Chief Scientific Officer of Rinat, the biotech unit of Pfizer, San Francisco, California (15 mn)

9:35 CAR architecture & CAR application Dr. Alexandre Juillerat, Ph.D. – Project Leader (20 mn)

9:55 BREAK

10:05 About UCART19 and UCART123 Dr. Julianne Smith, Ph.D. – Vice President, CART Development (20 mn)

10:25 Eric Falcand – Director, Alliance Management & US Licenses at Servier Laboratories (15 mn)

10:40 Manufacturing & Regulatory Stéphan Reynier – Head of Regulatory (15 mn)

10:55 Closing remarks and future perspectives for our allogeneic technology Dr. Mathieu Simon, MD – Executive Vice President (20 mn)


Download the PDF file